SUNNYVALE, Calif., April 7, 2014 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY) announced today that the European CyberKnife Center Munich-Grosshadern (ECZM) has performed 5,000 CyberKnife® treatments since June 2005. The center uses a CyberKnife M6™ System from the latest generation series, the most advanced robotic radiosurgery system in the world. Patients of the center benefit from a treatment option that offers enhanced stereotactic radiosurgery/stereotactic body radiation therapy (SRS/SBRT): tumors are treated non-invasively with precisely delivered high doses of radiation.
The European CyberKnife Center, in partnership with the University Hospital of Munich-Großhadern, offers almost 10 years of experience with this state-of-the-art technology. "The treatment with the CyberKnife System offers a number of benefits compared to surgery: no anesthesia, no pain and minimal side effects," explains Prof. Alexander Muacevic, who founded the treatment center together with his colleague Prof. Berndt Wowra in 2005. The CyberKnife System is used for tumors anywhere in the body. Prof. Muacevic added, "We treat brain tumors as well as tumors in the spine, the lung, the liver, and the prostate with good clinical outcomes. This remarkable technology is based on an integration of the latest developments in the field of image guidance, computer sciences and robotic radiation delivery."
The CyberKnife System features a compact linear accelerator mounted on a robotic arm. It is the only system that automatically adjusts the beam delivery to motion during treatment in real-time. This precision is essential to deliver high doses to the target area while simultaneously minimizing radiation exposure to surrounding healthy tissue and organs. The CyberKnife M6 System can deliver non-coplanar, non-isocentric beams from a wider number of angles around the patient, with the ability to follow tumors in real-time throughout the treatment. This provides clinicians the confidence to reduce margins for every disease that is treatable with the CyberKnife System.
"Accuray is proud of the cooperation with the European CyberKnife Center. We congratulate the European CyberKnife team on this tremendous achievement, and are pleased our precise, innovative tumor treatments are available to patients in such a highly experienced center," said Lionel Hadjadjeba, SVP Business International & GM EIMEA, Accuray International.
About Accuray Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company that develops, manufactures and sells precise, innovative treatment solutions that set the standard of care with the aim of helping patients live longer, better lives. The company's leading-edge technologies deliver the full range of radiation therapy and radiosurgery treatments.
About the European CyberKnife Center, Germany Besides the clinical and scientific cooperation with the Neurosurgical Department and the Institute of Clinical Radiology of the University of Munich, the CyberKnife Center Munich collaborates internationally with colleagues around the world. Close partnerships exist with the University Hospital Charite Berlin (http://cyberknife.charite.de) and the Stanford University, California/ USA.
Furthermore a scientific partnership is maintained with the Institute of Robotics and Cognitive Systems of the University Lübeck (Director: Professor Dr. Schweikard) where essential parts of the CyberKnife System have been developed (navigation software). Via the most modern telecommunication systems special cases are discussed with other dedicated experts around the world. Also, scientific projects are conducted on an international basis.Being part of the Radiosurgery Society's (http://www.therss.org) Board of Directors we put great effort in the development of internationally appreciated standards for treatment, education and quality control.
Safe Harbor Statement Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited to, the level of development of new technologies, clinical experience, clinical applications, clinical results, patient experiences and outcomes, and the company's leadership position in radiation oncology innovation and technology. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including risks detailed under the heading "Risk Factors" in the company's report on Form 10-K filed on August 29, 2013, the company's report on Form 10-Q filed on February 7, 2014, and as updated periodically by the company's other filings.
Forward-looking statements speak only as of the date the statements are made and are based on information available to the company at the time those statements are made and/or management's good faith belief as of that time with respect to future events. Accuray assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not place undue reliance on any forward-looking statements.
SOURCE Accuray Incorporated